Spiderwort Biotechnologies Inc., a leading biotechnology firm specializing in cellulose-based regenerative medicine, has announced that it has received Investigational Testing Authorization (ITA) from Health Canada for its innovative dermal filler, CelluJuve®. This approval marks a significant milestone for the company, allowing it to proceed with human clinical trials in Canada to assess the safety and performance of CelluJuve® for tissue augmentation and rejuvenation.
The clinical trials will focus on evaluating how CelluJuve® interacts with human tissues. This ITA follows the company’s successful completion of biocompatibility testing under ISO 10993 standards and human skin safety assessments for the product.
“This is a pivotal moment for Spiderwort as we continue our mission to revolutionize regenerative medicine,” said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies. “The approval validates our development approach and accelerates our efforts to bring CelluJuve® to the market as an innovative alternative in the dermal filler space. We look forward to demonstrating the potential of our Aerocel™ cellulose-based technology in medical aesthetics and other applications.”
Dr. Joely Kaufman, MD, FAAD, a member of Spiderwort’s Clinical Advisory Board and board-certified dermatologist with expertise in facial aesthetics, expressed optimism about CelluJuve®’s potential. “The preliminary data indicates that this cellulose-based filler could offer a novel solution for addressing facial aging. I’m eager to see how the clinical trials unfold.”
CelluJuve® is being developed as a cellulose-based alternative to traditional dermal fillers. It is designed to interact with the body to promote natural collagen production, offering a more organic look and feel. Initial research focuses on using CelluJuve® for nasolabial fold correction, a common area of concern for those seeking facial rejuvenation.
Spiderwort’s newly established ISO 5 cleanroom facility, announced earlier this year, will be used to produce medical-grade CelluJuve® for the upcoming trials, ensuring that all materials meet the highest safety and quality standards.
Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies, praised the company’s innovative approach, stating, “CelluJuve® demonstrates the incredible potential of plant-derived biomaterials to address medical needs. These regulatory achievements highlight the transformative power of nature-inspired innovation and its potential to regenerate and rejuvenate human tissues.”
While CelluJuve® has been authorized for clinical trials in Canada, it has not yet received approval from Health Canada or the U.S. Food and Drug Administration (FDA) for commercial use. The safety and efficacy of CelluJuve® in humans will be fully evaluated during the upcoming clinical trials.
Related topics:
